Ryan J. Watts sold $581k of DNLI
President and CEO at Denali Therapeutics Inc.. 35,198 shares at an average of $16.50, traded Jan 6, 2026, filed Jan 8, 2026.
Score components
- +25RoleCEO
- +19Trade size$581k at market
- +5Share of holdings soldSold 11% of holdings
- +8Cluster2 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001724310-26-000004, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 6, 2026 | SOpen-market sale Common Stock | -35,198 | $16.50 | $581k | 296,833 | Jan 8, 2026 |
Related signals
Other insiders at Denali Therapeutics Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 36Weak | Denali Therapeutics Inc. | Peter Scott Chin Chief Medical Officer | $37k 1,654 shares | -1% | |
| 33Weak | Denali Therapeutics Inc. | Nancy Thornberry director | $262k 11,439 shares | -37% | |
| 18Weak | Denali Therapeutics Inc. | Alexander O. Schuth COFO and Secretary | $65k 2,768 shares | -1% | |
| 37Weak | Denali Therapeutics Inc. | Alexander O. Schuth COFO and Secretary | $284k 17,218 shares | -6% | |
| 10Weak | Denali Therapeutics Inc. | Carole Ho Chief Medical Officer | $52k 3,743 shares | -2% | |
| 29Weak | Denali Therapeutics Inc. | Alexander O. Schuth COFO and Secretary | $40k 2,937 shares | -1% | |
| 35Weak | Denali Therapeutics Inc. | Ryan J. Watts President and CEO | $7.4M 495,282 shares | -66% | |
| 43Moderate | Denali Therapeutics Inc. | Steve E. Krognes director | $69k 3,339 shares | -11% | |
| 67Notable | Denali Therapeutics Inc. | Ryan J. Watts President and CEO | $751k 36,916 shares | -13% | |
| 44Moderate | Denali Therapeutics Inc. | Alexander O. Schuth COFO and Secretary | $308k 15,162 shares | -6% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.